Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 905749, 12 pages
http://dx.doi.org/10.1155/2015/905749
Review Article

Application of Berberine on Treating Type 2 Diabetes Mellitus

1Department of Endocrinology, Guang’anmen Hospital of China, Academy of Chinese Medical Sciences, Beijing 100054, China
2Laboratory of Molecular and Biology, Guang’anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 100054, China
3Department of Digestion, Beijing Hospital of Traditional Chinese Medicine, Capital University of Medicine Sciences, Beijing 100010, China

Received 22 December 2014; Accepted 24 February 2015

Academic Editor: Hyun C. Lee

Copyright © 2015 Bing Pang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. International Diabetes Federation, IDF Diabetes Altas Globally, IDF, 6th edition, 2013.
  2. Z. J. Wang, J. Wang, and P. Chan, “Treating type 2 diabetes mellitus with traditional Chinese and Indian medicinal herbs,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 343594, 17 pages, 2013. View at Publisher · View at Google Scholar
  3. W. D. Xie, Y. N. Zhao, and Y. O. Zhang, “Traditional Chinese medicines in treatment of patients with type 2 diabetes mellitus,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 726723, 13 pages, 2011. View at Publisher · View at Google Scholar
  4. P. Zimmet, K. G. M. M. Alberti, and J. Shaw, “Global and societal implications of the diabetes epidemic,” Nature, vol. 414, no. 6865, pp. 782–787, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Asante, “Interventions to promote treatment adherence in type 2 diabetes mellitus,” British Journal of Community Nursing, vol. 18, no. 6, pp. 267–274, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. A. A. Agarwal, P. R. Jadhav, and Y. A. Deshmukh, “Prescribing pattern and efficacy of anti-diabetic drugs in maintaining optimal glycemic levels in diabetic patients,” Journal of Basic and Clinical Pharmacy, vol. 5, no. 3, pp. 79–83, 2014. View at Publisher · View at Google Scholar
  7. J. Nagpal and A. Bhartia, “Quality of diabetes care in the middle- and high-income group populace: the Delhi Diabetes Community (DEDICOM) survey,” Diabetes Care, vol. 29, no. 11, pp. 2341–2348, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. P. F. Valerón and P. L. de Pablos-Velasco, “Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus,” Medicina Clínica, vol. 141, supplement 2, pp. 20–25, 2013. View at Publisher · View at Google Scholar
  9. Authority of the Board of the American Socitey of Health-System Pharamcists, AHFS Drug Information, American Hospital Formulary Service, Bethesda, Md, USA, 2012.
  10. M. Hanefeld, X. Ganz, and C. Nolte, “Hypoglycemia and cardiac arrhythmia in patients with diabetes mellitus type 2,” Herz, vol. 39, no. 3, pp. 312–319, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. H. B. Shi and Q. Cai, “Summary on adverse reactions of antidiabetic drugs,” Zhong Guo Yao Wu Jing Jie, vol. 10, no. 3, pp. 159–162, 2013. View at Google Scholar
  12. S. El-Kaissi and S. Sherbeeni, “Pharmacological management of type 2 diabetes mellitus: an update,” Current Diabetes Reviews, vol. 7, no. 6, pp. 392–405, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. W. L. Li, H. C. Zheng, J. Bukuru, and N. De Kimpe, “Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus,” Journal of Ethnopharmacology, vol. 92, no. 1, pp. 1–21, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. Q. Wang, “The present situation of TCM treatment for diabetes and its researches,” Journal of Traditional Chinese Medicine, vol. 23, no. 1, pp. 67–73, 2003. View at Google Scholar · View at Scopus
  15. T.-F. Tzeng, S.-S. Liou, and I.-M. Liu, “The selected traditional chinese medicinal formulas for treating diabetic nephropathy: perspective of modern science,” Journal of Traditional and Complementary Medicine, vol. 3, no. 3, pp. 152–158, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. P. K. Prabhakar and M. Doble, “Mechanism of action of natural products used in the treatment of diabetes mellitus,” Chinese Journal of Integrative Medicine, vol. 17, no. 8, pp. 563–574, 2011. View at Publisher · View at Google Scholar
  17. H. Dong, N. Wang, L. Zhao, and F. Lu, “Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 591654, 12 pages, 2012. View at Publisher · View at Google Scholar
  18. H. Dong, Y. Zhao, L. Zhao, and F. Lu, “The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials,” Planta Medica, vol. 79, no. 6, pp. 437–446, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Derosa, P. Maffioli, and A. F. G. Cicero, “Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials,” Expert Opinion on Biological Therapy, vol. 12, no. 8, pp. 1113–1124, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. I. P. Singh and S. Mahajan, “Berberine and its derivatives: a patent review (2009–2012),” Expert Opinion on Therapeutic Patents, vol. 23, no. 2, pp. 215–231, 2013. View at Publisher · View at Google Scholar
  21. P. R. Vuddanda, S. Chakraborty, and S. Singh, “Berberine: a potential phytochemical with multispectrum therapeutic activities,” Expert Opinion on Investigational Drugs, vol. 19, no. 10, pp. 1297–1307, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. Q. M. Chen and M. Z. Xie, “Studies on the hypoglycemic effect of Coptis chinensis and berberine,” Acta Pharmaceutica Sinica, vol. 21, no. 6, pp. 401–406, 1986 (Chinese). View at Google Scholar · View at Scopus
  23. Q. Zhang, X. Xiao, K. Feng et al., “Berberine moderates glucose and lipid metabolism through multipathway mechanism,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 924851, 10 pages, 2011. View at Publisher · View at Google Scholar
  24. J. Yang, J. Yin, H. Gao, L. Xu, Y. Wang, and M. Li, “Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients,” Evidence-based Complementary and Alternative Medicine, vol. 2012, Article ID 363845, 9 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. W.-H. Chueh and J.-Y. Lin, “Berberine, an isoquinoline alkaloid in herbal plants, protects pancreatic islets and serum lipids in nonobese diabetic mice,” Journal of Agricultural and Food Chemistry, vol. 59, no. 14, pp. 8021–8027, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. W. H. Chueh and J. Y. Lin, “Protective effect of berberine on serum glucose levels in non-obese diabetic mice,” International Immunopharmacology, vol. 12, no. 3, pp. 534–538, 2012. View at Publisher · View at Google Scholar
  27. W.-J. Kong, H. Zhang, D.-Q. Song et al., “Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression,” Metabolism: Clinical and Experimental, vol. 58, no. 1, pp. 109–119, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. S. H. Kim, E.-J. Shin, E.-D. Kim, T. Bayaraa, S. C. Frost, and C.-K. Hyun, “Berberine activates GLUT1-mediated glucose uptake in 3T3-L1 adipocytes,” Biological and Pharmaceutical Bulletin, vol. 30, no. 11, pp. 2120–2125, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. B.-S. Ko, S. B. Choi, S. K. Park, J. S. Jang, Y. E. Kim, and S. Park, “Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma,” Biological and Pharmaceutical Bulletin, vol. 28, no. 8, pp. 1431–1437, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Zhang, Y.-C. Xu, F.-J. Guo, Y. Meng, and M.-L. Li, “Anti-diabetic effects of cinnamaldehyde and berberine and their impacts on retinol-binding protein 4 expression in rats with type 2 diabetes mellitus,” Chinese Medical Journal, vol. 121, no. 21, pp. 2124–2128, 2008. View at Google Scholar · View at Scopus
  31. C. Chen, Y. Zhang, and C. Huang, “Berberine inhibits PTP1B activity and mimics insulin action,” Biochemical and Biophysical Research Communications, vol. 397, no. 3, pp. 543–547, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. S. Lee, W. S. Kim, K. H. Kim et al., “Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states,” Diabetes, vol. 55, no. 8, pp. 2256–2264, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. J.-T. Hwang, D. Y. Kwon, and S. H. Yoon, “AMP-activated protein kinase: a potential target for the diseases prevention by natural occurring polyphenols,” New Biotechnology, vol. 26, no. 1-2, pp. 17–22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. B. B. Kahn, T. Alquier, D. Carling, and D. G. Hardie, “AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism,” Cell Metabolism, vol. 1, no. 1, pp. 15–25, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Yin, Z. Gao, D. Liu, Z. Liu, and J. Ye, “Berberine improves glucose metabolism through induction of glycolysis,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 294, no. 1, pp. E148–E156, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. Z. Cheng, T. Pang, M. Gu et al., “Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK,” Biochimica et Biophysica Acta—General Subjects, vol. 1760, no. 11, pp. 1682–1689, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Yu, L. Liu, X. Wang, X. Liu, L. Xie, and G. Wang, “Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies,” Biochemical Pharmacology, vol. 79, no. 7, pp. 1000–1006, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. S.-S. Lu, Y.-L. Yu, H.-J. Zhu et al., “Berberine promotes glucagon-like peptide-1 (7–36) amide secretion in streptozotocin-induced diabetic rats,” Journal of Endocrinology, vol. 200, no. 2, pp. 159–165, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. X. Xia, J. Yan, Y. Shen et al., “Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis,” PLoS ONE, vol. 6, no. 2, Article ID e16556, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. Z.-Q. Wang, F.-E. Lu, S.-H. Leng et al., “Facilitating effects of berberine on rat pancreatic islets through modulating hepatic nuclear factor 4 alpha expression and glucokinase activity,” World Journal of Gastroenterology, vol. 14, no. 39, pp. 6004–6011, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Berger and D. E. Moller, “The mechanisms of action of PPARs,” Annual Review of Medicine, vol. 53, pp. 409–435, 2002. View at Google Scholar
  42. J. Y. Zhou, S. W. Zhou, K. B. Zhang et al., “Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats,” Biological and Pharmaceutical Bulletin, vol. 31, no. 6, pp. 1169–1176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Schoonjans, B. Staels, and J. Auwerx, “The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation,” Biochimica et Biophysica Acta: Lipids and Lipid Metabolism, vol. 1302, no. 2, pp. 93–109, 1996. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Huang, Y. Zhang, Z. Gong et al., “Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARγ pathway,” Biochemical and Biophysical Research Communications, vol. 348, no. 2, pp. 571–578, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Yin, H. Zhang, and J. Ye, “Traditional Chinese medicine in treatment of metabolic syndrome,” Endocrine, Metabolic and Immune Disorders—Drug Targets, vol. 8, no. 2, pp. 99–111, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Liu, Y.-L. Yu, J.-S. Yang et al., “Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 381, no. 4, pp. 371–381, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Liu, Y. Deng, S. Yu, S. Lu, L. Xie, and X. Liu, “Berberine attenuates intestinal disaccharidases in streptozotocin-induced diabetic rats,” Pharmazie, vol. 63, no. 5, pp. 384–388, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Han, H. Lin, and W. Huang, “Modulating gut microbiota as an anti-diabetic mechanism of berberine,” Medical Science Monitor, vol. 17, no. 7, pp. RA164–RA167, 2011. View at Google Scholar · View at Scopus
  49. G. S. Hotamisligil, “Inflammation and metabolic disorders,” Nature, vol. 444, no. 7121, pp. 860–867, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. P. D. Cani and N. M. Delzenne, “The role of the gut microbiota in energy metabolism and metabolic disease,” Current Pharmaceutical Design, vol. 15, no. 13, pp. 1546–1558, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. Z. X. Li, X. H. Wang, J. H. Zhao et al., “Studies on in vitro antibacterial activity of Coptis chinensis against 252 strains inclinic with muellerhinton agar,” Zhong Cao Yao, vol. 32, pp. 337–339, 2001. View at Google Scholar
  52. R. S. Iwazaki, E. H. Endo, T. Ueda-Nakamura, C. V. Nakamura, L. B. Garcia, and B. P. D. Filho, “In vitro antifungal activity of the berberine and its synergism with fluconazole,” Antonie van Leeuwenhoek, vol. 97, no. 2, pp. 201–205, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. D. Yan, C. Jin, X.-H. Xiao, and X.-P. Dong, “Antimicrobial properties of berberines alkaloids in Coptis chinensis Franch by microcalorimetry,” Journal of Biochemical and Biophysical Methods, vol. 70, no. 6, pp. 845–849, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. R. E. Ley, P. J. Turnbaugh, S. Klein, and J. I. Gordon, “Microbial ecology: human gut microbes associated with obesity,” Nature, vol. 444, no. 7122, pp. 1022–1023, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. J. K. DiBaise, H. Zhang, M. D. Crowell, R. Krajmalnik-Brown, G. A. Decker, and B. E. Rittmann, “Gut microbiota and its possible relationship with obesity,” Mayo Clinic Proceedings, vol. 83, no. 4, pp. 460–469, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. W. Xie, D. Gu, J. Li, K. Cui, and Y. Zhang, “Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice,” PLoS ONE, vol. 6, no. 9, Article ID e24520, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. X. Zhang, Y. Zhao, M. Zhang et al., “Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats,” PLoS ONE, vol. 7, no. 8, Article ID e42529, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. Z. Li, Y. N. Geng, J. D. Jiang, and W. J. Kong, “Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 289264, 12 pages, 2014. View at Publisher · View at Google Scholar
  59. W. Xie and L. Du, “Diabetes is an inflammatory disease: evidence from traditional Chinese medicines,” Diabetes, Obesity and Metabolism, vol. 13, no. 4, pp. 289–301, 2011. View at Publisher · View at Google Scholar
  60. J. Singh and P. Kakkar, “Antihyperglycemic and antioxidant effect of Berberis aristata root extract and its role in regulating carbohydrate metabolism in diabetic rats,” Journal of Ethnopharmacology, vol. 123, no. 1, pp. 22–26, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Golbidi and I. Laher, “Antioxidant therapy in human endocrine disorders,” Medical Science Monitor, vol. 16, no. 1, pp. RA9–RA24, 2010. View at Google Scholar · View at Scopus
  62. J.-Y. Zhou and S.-W. Zhou, “Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor b expression in diabetic rat liver,” Fitoterapia, vol. 82, no. 2, pp. 184–189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. P. Bhutada, Y. Mundhada, K. Bansod et al., “Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes,” Behavioural Brain Research, vol. 220, no. 1, pp. 30–41, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Wang, T. Campbell, B. Perry, C. Beaurepaire, and L. Qin, “Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats,” Metabolism: Clinical and Experimental, vol. 60, no. 2, pp. 298–305, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. W.-H. Liu, Z.-Q. Hei, H. Nie et al., “Berberine ameliorates renal injury in streptopzotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase,” Chinese Medical Journal, vol. 121, no. 8, pp. 706–712, 2008. View at Google Scholar · View at Scopus
  66. T. Lan, X. Shen, P. Liu et al., “Berberine ameliorates renal injury in diabetic C57BL/6 mice: involvement of suppression of SphK-S1P signaling pathway,” Archives of Biochemistry and Biophysics, vol. 502, no. 2, pp. 112–120, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. W. Liu, P. Liu, S. Tao et al., “Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose,” Archives of Biochemistry and Biophysics, vol. 475, no. 2, pp. 128–134, 2008. View at Publisher · View at Google Scholar
  68. H. Z. Yang, M. M. Zhou, A. H. Zhao et al., “Study on effects of baicalin, berberine and astragalus polysaccharides and their combinative effects on aldose reductase in vitro,” Zhong Yao Cai, vol. 32, no. 8, pp. 1259–1261, 2009. View at Google Scholar
  69. A. Dregan, J. Charlton, P. Chowienczyk, and M. C. Gulliford, “Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study,” Circulation, vol. 130, no. 10, pp. 837–844, 2014. View at Publisher · View at Google Scholar
  70. H. W. Jeong, K. C. Hsu, M. Ham et al., “Berberine suppresses pro-inflammatory responses through AMPK activation in macrophages,” American Journal of Physiology—Endocrinology and Metabolism, vol. 296, no. 4, pp. E955–E964, 2009. View at Publisher · View at Google Scholar
  71. T. Lou, Z. Zhang, Z. Xi et al., “Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes,” Inflammation, vol. 34, no. 6, pp. 659–667, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. Q. Jiang, P. Liu, X. Wu et al., “Berberine attenuates lipopolysaccharide-induced extracelluar matrix accumulation and inflammation in rat mesangial cells: involvement of NF-κB signaling pathway,” Molecular and Cellular Endocrinology, vol. 331, no. 1, pp. 34–40, 2011. View at Publisher · View at Google Scholar
  73. Y. Wang, “Attenuation of berberine on lipopolysaccharide-induced inflammatory and apoptosis responses in β-cells via TLR4-independent JNK/NF-κB pathway,” Pharmaceutical Biology, vol. 52, no. 4, pp. 532–538, 2014. View at Publisher · View at Google Scholar
  74. L. Q. Tang, W. Wei, L. M. Chen, and S. Liu, “Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats,” Journal of Ethnopharmacology, vol. 108, no. 1, pp. 109–115, 2006. View at Publisher · View at Google Scholar
  75. W. Kong, J. Wei, P. Abidi et al., “Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins,” Nature Medicine, vol. 10, no. 12, pp. 1344–1351, 2004. View at Publisher · View at Google Scholar · View at Scopus
  76. W. J. Kong, J. Liu, and J. D. Jiang, “Human low-density lipoprotein receptor gene and its regulation,” Journal of Molecular Medicine (Berlin), vol. 84, no. 1, pp. 29–36, 2006. View at Google Scholar
  77. P. Abidi, Y. Zhou, J.-D. Jiang, and J. Liu, “Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 10, pp. 2170–2176, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. Lee S, H. J. Lim, J. H. Park, K. S. Lee, Y. Jang, and H. Y. Park, “Berberine-induced LDLR up-regulation involves JNK pathway,” Biochemical and Biophysical Research Communications, vol. 362, no. 4, pp. 853–857, 2007. View at Google Scholar
  79. J.-M. Brusq, N. Ancellin, P. Grondin et al., “Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine,” Journal of Lipid Research, vol. 47, no. 6, pp. 1281–1288, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. J. Yin, H. Xing, and J. Ye, “Efficacy of berberine in patients with type 2 diabetes mellitus,” Metabolism: Clinical and Experimental, vol. 57, no. 5, pp. 712–717, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. H. Zhang, J. Wei, R. Xue et al., “Berberine lowers blood glucose in type 2 diabetes mellitus Patients through increasing insulin receptor expression,” Metabolism: Clinical and Experimental, vol. 59, no. 2, pp. 285–292, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. Y. Zhang, X. Li, D. Zou et al., “Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 7, pp. 2559–2565, 2008. View at Publisher · View at Google Scholar
  83. Z. X. Sheng and D. H. Xie, “Therapeutic effect of berberine on the levels of inflammatory factors in type 2 diabetic patients,” New Medicine, vol. 41, no. 3, pp. 177–180, 2010. View at Google Scholar
  84. S. L. Yin, H. Q. Yin, C. H. Li, and C. M. Liu, “The effects of berberine hydrochloride on blood glucose, insulin and lipids levels in newly diagnosed type 2 diabetic patients,” Xu Zhou Yi Xue Yuan Xue Bao, vol. 31, no. 1, pp. 40–41, 2011. View at Google Scholar
  85. Z. Li and L. H. Liu, “Therapeutic efficacy of combined berberine and glipizide on type 2 diabetes mellitus,” Yi Xue Lin Chuang Za Zhi, vol. 24, no. 1, pp. 61–64, 2007. View at Google Scholar
  86. S. B. Pu, H. X. Xu, Y. H. Zhang et al., “Individual difference of growth condition and alkaloid content of Chinese gold thread (Coptis chinensis),” Zhong Cao Yao, vol. 30, no. 5, pp. 375–377, 1999. View at Google Scholar
  87. Y. P. Zhang, L. Han, Q. H. Yang et al., “Discussion on the medicinal properties and efficacy of berberine,” Zhong Guo Yi Yao Ke Xue, vol. 2, no. 21, pp. 52–53, 2012. View at Google Scholar
  88. D. Wu and J. Wei, “Clinical observation on berberine treating type 2 diabetes mellitus,” Acta Universitatis Medicinalis Nanjing, vol. 29, no. 5, pp. 736–738, 2009. View at Google Scholar
  89. H. Tang and Y. Shen, “Clinical study on hypoglycemic effect of berberine on different TCM syndromes of type 2 diabetes,” Shang Hai Zhong Yi Yao Za Zhi, vol. 42, no. 12, pp. 22–24, 2008. View at Google Scholar
  90. J. Guo, H. D. Chen, J. Song, J. Wang, L. Zhao, and X. Tong, “Syndrome differentiation of diabetes by the traditional Chinese medicine,” Evidence-Based Complementary and Alternative Medicine, vol. 2004, Article ID 492193, 7 pages, 2004. View at Publisher · View at Google Scholar
  91. T. Zhang and M. J. Chen, “Research progresses on the anti-hyperglycemic effect of berberine,” Zhong Guo Shi Yong Yi Yao, vol. 4, no. 22, pp. 246–248, 2009. View at Google Scholar
  92. B. Guo and H. X. Zhao, “Hypoglycemic pharmacodynamics and clinical efficacy of berberine,” Zhong Guo Yao Ye, vol. 15, no. 21, pp. 30–31, 2006. View at Google Scholar
  93. W. Hua, L. Ding, Y. Chen, B. Gong, J. He, and G. Xu, “Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry,” Journal of Pharmaceutical and Biomedical Analysis, vol. 44, no. 4, pp. 931–937, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. X. L. Bian, L. C. He, and G. D. Yang, “Synthesis and anti-hyperglycemic evaluation of various protoberberine derivatives,” Bioorganic & Medicinal Chemistry Letters, vol. 16, pp. 1380–1383, 2006. View at Google Scholar
  95. Z. Cheng, A. F. Chen, F. Wu et al., “8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models,” Bioorganic & Medicinal Chemistry, vol. 18, no. 16, pp. 5915–5924, 2010. View at Publisher · View at Google Scholar
  96. N. Turner, J.-Y. Li, A. Gosby et al., “Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate amp-activated protein kinase and improve insulin action,” Diabetes, vol. 57, no. 5, pp. 1414–1418, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. V. P. Torchilin, “Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery,” Nature Reviews Drug Discovery, vol. 13, no. 11, pp. 813–827, 2014. View at Publisher · View at Google Scholar
  98. R. Kapoor, S. Singh, M. Tripathi, P. Bhatnagar, P. Kakkar, and K. C. Gupta, “O-hexadecyl-dextran entrapped berberine nanoparticles abrogate high glucose stress induced apoptosis in primary rat hepatocytes,” PLoS ONE, vol. 9, no. 2, Article ID e89124, 2014. View at Publisher · View at Google Scholar
  99. S. Pund, G. Borade, and G. Rasve, “Improvement of anti-inflammatory and anti-angiogenic activity of berberine by novel rapid dissolving nanoemulsifying technique,” Phytomedicine, vol. 21, no. 3, pp. 307–314, 2014. View at Publisher · View at Google Scholar · View at Scopus
  100. S. Y. Yang and X. H. Wang, “Discussion between Chinese herbal researches on skin infections of newborn infants and ‘jaundice of the newborn baby caused by Rhizoma Coptidis’,” Yi Xue Yan Jiu, vol. 37, no. 7, p. 95, 2008. View at Google Scholar
  101. C. L. Liao, Preliminary Observation on Physiological Jaundice (Fetal Jaundice) of the Newborn Baby Related by Yinchen Hao Decoction and Rhizoma Coptidis, vol. 13, Private School of Chinese Medicine Researches of Annual Report, 1982.
  102. B. L. Ma, Y. M. Ma, R. Shi et al., “Identification of the toxic constituents in Rhizoma Coptidis,” Journal of Ethnopharmacology, vol. 128, no. 2, pp. 357–364, 2010. View at Publisher · View at Google Scholar
  103. M. M. Kheir, Y. Wang, L. Hua et al., “Acute toxicity of berberine and its correlation with the blood concentration in mice,” Food and Chemical Toxicology, vol. 48, no. 4, pp. 1105–1110, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. Q. M. G. Na, T. Y. Zhao, M. He, and C. Tian, “Effectiveness and safety of berberine in the treatment of type 2 diabetes: a systematic review,” Zhong Guo Xun Zheng Yi Xue Za Zhi, vol. 12, no. 1, pp. 81–91, 2012. View at Google Scholar
  105. C. Vincent and A. Furnham, “Why do patients turn to complementary medicine? An empirical study,” British Journal of Clinical Psychology, vol. 35, no. 1, pp. 37–48, 1996. View at Publisher · View at Google Scholar · View at Scopus
  106. R. A. Bell, C. K. Suerken, J. G. Grzywacz, W. Lang, S. A. Quandt, and T. A. Arcury, “Complementary and alternative medicine use among adults with diabetes in the United States,” Alternative Therapies in Health and Medicine, vol. 12, no. 5, pp. 16–22, 2006. View at Google Scholar · View at Scopus
  107. M.-S. Lee, M. S. Lee, H.-J. Lim, and S.-R. Moon, “Survey of the use of complementary and alternative medicine among Korean diabetes mellitus patients,” Pharmacoepidemiology and Drug Safety, vol. 13, no. 3, pp. 167–171, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. X. Tu, C. G. Xie, F. Wang et al., “Fructus mume formula in the treatment of type 2 diabetes mellitus: a randomized controlled pilot trial,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 787459, 8 pages, 2013. View at Publisher · View at Google Scholar